Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.5M | $17.2M | $26.9M | $36.6M | $45.6M | $68.8M | $75.7M | $84.5M | $57.7M | $63.3M |
| Revenue growth | — | 4.6% | 55.9% | 36.3% | 24.5% | 50.9% | 10.1% | 11.6% | -31.8% | 9.7% |
| Operating income | -$65.7M | -$89.8M | -$120M | -$111M | -$94.3M | -$189M | -$204M | -$142M | -$110M | -$70.2M |
| Operating margin | -398.7% | -520.7% | -446.4% | -302.5% | -206.7% | -274.1% | -268.8% | -168.4% | -191.4% | -111.0% |
| Net income | -$55.1M | -$66.9M | -$84.1M | -$40.0M | -$46.5M | -$64.7M | -$86.6M | -$60.6M | -$46.0M | $6.82M |
| Net margin | -334.3% | -387.8% | -313.0% | -109.1% | -102.0% | -94.1% | -114.3% | -71.7% | -79.8% | 10.8% |
| EPS (diluted) | -$1.38 | -$1.61 | -$1.94 | -$0.73 | -$0.65 | -$0.79 | -$15.97 | -$8.47 | -$2.69 | -$0.07 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$45.8M | -$81.3M | -$98.8M | -$95.0M | -$83.7M | -$117M | -$179M | -$128M | -$80.2M | -$65.8M |
| Capital expenditures | $6.37M | $648K | $7.08M | $2.35M | $1.93M | $4.57M | $2.71M | $63.0K | $0.00 | — |
| Free cash flow | -$52.2M | -$82.0M | -$106M | -$97.3M | -$85.6M | -$121M | -$182M | -$128M | -$80.2M | — |
| Share buybacks | — | — | — | $0.00 | $70.0K | — | — | — | — | — |
| Dividends paid | — | — | — | $0.00 | $237K | $749K | $749K | $736K | $694K | $664K |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $88.3M | $95.0M | $65.5M | $137M | $233M | $306M | $178M | $80.9M | $57.3M | $79.4M |
| Total assets | $171M | $246M | $141M | $226M | $333M | $397M | $294M | $168M | $144M | $186M |
| Total liabilities | $87.8M | $125M | $121M | $154M | $136M | $171M | $244M | $166M | $146M | $123M |
| Long-term debt | $30.2M | $67.5M | $84.4M | $84.7M | $51.7M | $42.9M | $91.7M | $60.9M | $58.0M | $52.4M |
| Shareholders' equity | $38.5M | $52.6M | $1.85M | $26.2M | $100M | $109M | $41.7M | $22.5M | $22.7M | $49.9M |
| Retained earnings | -$245M | -$312M | -$396M | -$436M | -$483M | -$547M | -$634M | -$695M | -$741M | -$734M |
| Shares (wtd avg diluted) | 48.9M | 51.0M | 57.8M | 74.0M | 94.9M | 81.7M | 5.92M | 8.11M | 20.8M | 27.9M |
Every figure is extracted from Fortress Biotech, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.